Dr Graham on Data for JNJ-87189401 Plus Pasritamig in mCRPC
Johnson & Johnson's JNJ-87189401 plus pasritamig showed promising results in mCRPC patients at the 2026 SITC Annual Meeting. The recommended dose had no severe adverse effects, with 73.3% achieving a PSA decline of at least 50%. The combination is being evaluated in a phase 3 trial.
How this was made
The 30-second read
Why it matters
The data provide the first efficacy signal for JNJ-87189401, potentially influencing upcoming Phase 3 design and market expectations.
Market read
Positive early data could drive short-term buying interest in JNJ and related oncology stocks.
What to watch
Long-term safety and comparative advantage versus existing treatments remain uncertain.
Background
Phase 2 trial presented at SITC Annual Meeting, evaluating a novel antibody-drug conjugate in heavily pretreated patients.
Ticker impact
First public disclosure of Phase 2 data for JNJ-87189401 and pasritamig in metastatic castration-resistant prostate cancer.
upward pressure as market prices in the favorable efficacy data.
Phase 2 data showing high PSA response rates and manageable safety profile can boost investor confidence.
Market effects
May lift other biotech firms developing prostate cancer therapies.
US biotech sector could see modest gains.
Limited to investors tracking oncology pipeline developments.
Counterpoint
Data are early-stage; efficacy may not translate to later trials, risk of disappointment.
Key entities
- CompanyJohnson & Johnson
Developer of JNJ-87189401.
